Table III.
Immunological and clinical response to vaccination.
| Patient | Vaccine dose (mg) | Cycles completed | Pre-trial WT1 tetramer (% of CD8+) | Maximum post-vaccination tetramer (% of CD8+) and time point | Tetramer response >1·5 × pre-trial? | IFN-γ response by ELISPOT | Time from start of study to disease progression | ||
|---|---|---|---|---|---|---|---|---|---|
| pWT126 | pWT235 | PADRE | |||||||
| RFH 001 | 0·3 | 5 | 0·1 | 0·2 maximum week 9 | + | + | + | + | 9 months |
| RFH 002 | 1·0 | 4 | 0·1 | 0·2 maximum week 9 | + | + | + | + | 39 months |
| RFH 003 | 1·0 | 5 | 0·1 | 0·8 maximum week 12 | + | + | + | + | >41 months |
| UCH 001 | 0·3 | 5 | N/A | 1·4 N/A | N/A | N/A | N/A | N/A | 18 months |
| UCH 002 | 0·3 | 4 | 0·2 | 0·2 N/A | − | + | + | + | 9 weeks |
| UCH 003 | 0·6 | 5 | 0·0 | 0·5 maximum week 15 | + | + | + | + | 7 months |
| BHM 001 | 0·6 | 2 | 0·1 | 0·4 maximum week 6 | + | − | − | − | 6 weeks |
| BHM 002 | 0·6 | 5 | 0·0 | 4·2 maximum week 6 | + | + | + | + | 10 months |
RFH, Royal Free Hospital, London; UCH, University College Hospital, London; BHM, Queen Elizabeth Hospital, Birmingham; ELISPOT, enzyme-linked immunosorbent spot; N/A, not applicable.